Key result
VT ablation using ICE linked to ~24% fewer 12-month VT-related readmissions versus no ICE.
Why the study?
Intracardiac echocardiography (ICE) provides real-time monitoring of the catheter-tissue interface and complications during ventricular tachycardia (VT) ablation, which may improve clinical outcomes.
Does the use of intracardiac echocardiography during ventricular tachycardia catheter ablation reduce 12-month readmission rates, repeat ablation, and complications in patients with structural heart disease and ICD/CRT-D?
Cohort (n=1,324)
Yes
Does the use of intracardiac echocardiography during ventricular tachycardia catheter ablation reduce 12-month readmission rates, repeat ablation, and complications in patients with structural heart disease and ICD/CRT-D?
Effect estimate: OR 0.76 (95% CI 0.58-0.99)
Absolute Event Rate: 18.13% vs 22.51%
p-value: p=< .05
The use of intracardiac echocardiography during VT ablation in patients with structural heart disease is associated with reduced 12-month VT-related readmissions and repeat ablations without increasing complications.
May support ICE in VT ablation to lower readmissions; extends observational data but leaves open randomized confirmation.
INTRODUCTION: By providing real-time monitoring of catheter-tissue interface and for complications, intracardiac echocardiography (ICE) during catheter ablation for ventricular tachycardia (VT) may improve outcomes. To test this hypothesis, we compared 12-month readmission rates (all-cause, cardiovascular [CV]-related, and VT-related), repeat ablation, and complications among patients with VT with structural heart disease undergoing ablation with versus without ICE. METHODS AND RESULTS: Using the 2008-2017 IBM MarketScan Commercial and Medicare Supplemental databases, patients with a history of implantable cardioverter defibrillator/cardiac resynchronization therapy (ICD/CRT-D) who underwent VT ablation with and without ICE use were identified. Propensity matching was performed and regression analysis was used to compare outcomes. After matching, 1324 patients were identified (ICE: 662; non-ICE: 662). The rate of 12-month VT-related readmission (18.13% vs 22.51%; P < .05) and repeat VT ablation (14.35% vs 19.34%; P = .02) postindex discharge were lower among patients in the ICE group compared with the non-ICE group, with a 24% lower risk of 12-month VT-related readmission (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.58-0.99) and a 30% lower risk of repeat ablation (OR, 0.70; 95% CI, 0.52-0.93) vs non-ICE group. The 12-month all-cause (44.56% vs 43.20%; P = .62) and CV-related readmissions (35.20% vs 32.93%; P = 0.38) and complication rates were not significantly different between the two groups. CONCLUSIONS: VT ablation using ICE was associated with a lower likelihood of 12-month VT-related readmission and repeat ablation compared with non-ICE patients.
No takes yet. Share an insight, caveat, or question.
Field et al. (2019) conducted a cohort in Ventricular tachycardia with structural heart disease (n=1,324). Intracardiac echocardiography (ICE) during catheter ablation vs. Catheter ablation without ICE was evaluated on 12-month VT-related readmission (OR 0.76, 95% CI 0.58-0.99, p=< .05). VT ablation using intracardiac echocardiography was associated with a lower risk of 12-month VT-related readmission (OR 0.76; 95% CI 0.58-0.99) compared with ablation without ICE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: